title: Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials.
abstract: BACKGROUND
  The milk-derived peptides isoleucine-proline-proline (IPP) and valine-proline- proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations.
  
  
  METHODS
  A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect.
  
  
  RESULTS
  Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28mm Hg (95% CI, -2.09 to -0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59mm Hg (95% CI, -1.18 to -0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09mm Hg. This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension.
  
  
  CONCLUSIONS
  The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
authors: Internal Medicine, Aging and Kidney Disease Department, University of Bologna, Bologna, Italy. afgcicero@cardionet.it
authors: Arrigo F G
authors: AF
authors: Cicero
authors: Francois
authors: F
authors: Aubin
authors: Veronique
authors: V
authors: Azais-Braesco
authors: Claudio
authors: C
authors: Borghi
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D044466:Asian People; D001794:Blood Pressure / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008892:Milk / Q000737:chemistry; D009842:Oligopeptides / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D044465:White People
chemical_list: D000959:Antihypertensive Agents; D009842:Oligopeptides; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline
references: Cochrane Database Syst Rev. 2004;(3):CD004937
references: 15266549
references: Circulation. 2008 Sep 23;118(13):1383-93
references: 18809808
references: BMJ. 2009 Jul 21;339:b2700
references: 19622552
references: Am J Clin Nutr. 2003 Feb;77(2):326-30
references: 12540390
references: J Hum Hypertens. 2010 Oct;24(10):678-83
references: 20147968
references: J Hum Hypertens. 2008 Nov;22(11):804-6
references: 18528405
references: Expert Rev Cardiovasc Ther. 2009 Jun;7(6):659-65
references: 19505281
references: Cochrane Database Syst Rev. 2003;(1):CD004022
references: 12535503
references: Hypertens Res. 2011 Sep;34(9):1035-40
references: 21753776
references: N Engl J Med. 2006 Apr 20;354(16):1685-97
references: 16537662
references: J Hum Hypertens. 2011 Jul;25(7):425-36
references: 20811398
references: Heart Vessels. 2011 Sep;26(5):549-56
references: 21221598
references: J Dairy Sci. 1995 Jun;78(6):1253-7
references: 7673515
references: Eur J Pharmacol. 2009 Oct 12;620(1-3):71-7
references: 19686729
references: Nutrition. 2008 Oct;24(10):933-40
references: 18562172
references: Am J Clin Nutr. 2009 Feb;89(2):617-23
references: 19106238
references: Food Nutr Res. 2008;52:
references: 19109662
references: J Hypertens. 2010 Feb;28(2):395-400
references: 19864958
references: J Hum Hypertens. 2004 Nov;18(11):795-802
references: 15175633
references: Biometrics. 1994 Dec;50(4):1088-101
references: 7786990
references: J Mol Recognit. 2009 Mar-Apr;22(2):162-8
references: 18816584
references: N Engl J Med. 2007 Aug 23;357(8):789-96
references: 17715411
references: J Hum Hypertens. 1987 Sep;1(2):113-9
references: 3333522
references: Clin Physiol Funct Imaging. 2010 Mar;30(2):162-8
references: 20113315
references: Blood Press. 2009;18(1-2):44-50
references: 19247842
references: J Med Food. 2010 Dec;13(6):1363-8
references: 21091250
references: Food Funct. 2012 Jun;3(6):621-7
references: 22398753
references: Eur Heart J. 2007 Jun;28(12):1462-536
references: 17562668
references: Hypertension. 2008 Feb;51(2):399-405
references: 18086944
references: Hypertension. 2004 Jan;43(1):1-3
references: 14676222
references: Lancet. 2007 Aug 18;370(9587):591-603
references: 17707755
references: J Hypertens. 2008 Jul;26(7):1487-96
references: 18551027
references: Clin Ther. 2012 Mar;34(3):552-568, 568.e1-9
references: 22381711
references: Am J Clin Nutr. 2008 Dec;88(6):1697-702
references: 19064533